About Amsel Medical

Amsel Medical is a pre-commercialization stage medical device company founded in 2011 in Cambridge, MA. by world-renowned Vascular Surgeon Arnold Miller, MD. Amsel Medical boasts some of the industry’s most lauded professionals as part of the leadership team and Advisory Board. With three FDA Clearances and a CE Mark Clearance, the SCureClamp iDOT promises to meet unmet needs in the market and provide investors and physicians with a new standard of practice.

Learn more about the founding of Amsel Medical here.

 
 

Making precise, site specific, highly targeted interventions possible

GET IN TOUCH >


 
 

CHIEF EXECUTIVE OFFICER

James A. Heinz, MSL

39 years in healthcare. James founded the Center for Venous Disease and held key roles at Zimmer, Synthes, and Smith/Nephew in orthopedics and trauma. He also made significant contributions to the vascular space with VNUS Medical Technologies/ Medtronic and as a VENCLOSE C Suite Consultant/ Becton Dickinson. His expertise contributed to the successful exits in the chronic venous disease market at high valuation with VNUS and VENCLOSE. James holds a bachelor's degree in marketing and a master's degree in organizational leadership. Outside of healthcare, for over 15 years, James has been a United States Coast Guard Auxiliary Member supporting the operations of the United States Coast Guard under the supervision of the Department of Homeland Security.

 

 
 
arnold.png
AMSEL-logo.png

PRESIDENT & CMO

Arnold Miller, MD

Vascular Surgeon (Harvard Medical School, Mass General Hospital, MetroWest Medical Center) with more than 30 years experience treating venous reflux disease and peripheral vascular disease.

 

 
 

SENIOR VICE PRESIDENT, ENGINEERING

Jeff Willis

With over 25 years in healthcare engineering, Jeff Willis has a proven track record in research and development and manufacturing. He previously served as Director of Quality Assurance at Medline Industries, where he drove product excellence and regulatory compliance. Prior to that, Jeff held leadership roles at AngioDynamics, including Director of Research and Development, where he was instrumental in advancing key technologies and managing critical quality assurance functions. Jeff's commitment to quality and innovation continues to shape Amsel Medical’s engineering division. He holds an Engineering Degree from Cornell University.

 

 
AMSEL_medical_ranaan

VICE PRESIDENT, STRATEGIC DEVELOPMENT

Raanan Miller, Ph.D

15 years of startup experience. Founder and CTO of Sionex Corporation, a venture-backed startup that commercialized products with General Dynamics, Thermo Fisher Scientific, Varian Instruments, and NASA. Winner of Frost and Sullivan 2010 Best New Spectrometry Award. Holds 60+ issued patents. Ph.D. Caltech, MBA MIT Sloan School of Management.

1200px-Massachusetts_General_Hospital_logo.svg.jpg
california-institute-of-technology-caltech-vector-logo.png
 
 
 

 

In The News

 

Amsel Medical Announces Promotion of Jeff Willis to Senior Vice President of Engineering

Amsel Medical is proud to announce the promotion of Jeff Willis to Senior Vice President of Engineering. With over 25 years of experience in senior engineering, research and development, and manufacturing, Jeff will now oversee the continued innovation and strategic direction of Amsel Medical’s engineering division.

"We are thrilled to promote Jeff to this key leadership role," said James A. Heinz, Amsel Medical CEO. "His extensive experience and proven track record in driving engineering excellence make him the ideal leader to guide our team as we continue to push the boundaries of innovation." ….Read More

Amsel Medical Signs $7.45M Phase III SBIR Contract

Amsel Medical Corporation today announces that it has been awarded an $7.45 million sole source, non-dilutive, small business innovative research (SBIR) Phase III contract by the United States Air Force.  This award represents a significant milestone for the company and builds on successful prior AFWERX Phase I, Phase II and TACFI SBIR contracts with the U.S. Air Force.  …..Read More

Amsel Medical's Breakthrough Trauma Product Selected for Oral Presentation at the 2024 MHSRS

Amsel Medical announced the selection of an abstract “Saving Limbs and Lives: A Novel Percutaneous Vessel Occlusion Device to Combat Junctional Hemorrhage in Trauma”. This oral presentation will be delivered by MAJ Bobby Zhang, MD at the Young Investigator (YI) Competition Plenary session of the 2024 Military Health System Research Symposium (MHSRS). MAJ Zhang is a general surgery resident at Madigan Army Medical Center.…..Read More

AMSEL Medical Announces Appointment of Noam Karstaedt as a new Board Member

Amsel Medical today announced that Noam Karstaedt has been appointed to a new Board position effective February 29, 2024.  With the addition of this appointment, Amsel Medical will have five full time Board members and three Board Observers.

 David Doster, Amsel Medical CEO, commented that “We are pleased to welcome Noam to the Amsel Board at this time.  Noam has been actively involved in supporting Amsel as a Board Observer over the last several years…..Read More

Amsel Medical Signs Know-How Agreement with Mayo Clinic to Advance Occlusion Technology

Amsel Medical, a medical device company pioneering novel vessel occlusion devices for minimally invasive percutaneous, laparoscopic, open surgical, or robotic placement, today announced a collaboration through a know-how agreement with Mayo Clinic to advance the development of this novel occlusion technology based on the Amsel platform.

 “Saving Limbs, Saving Lives”

 The collaboration brings together Amsel’s patented Interdigitation Occlusion Technology (iDOT™) with Mayo Clinic’s clinical know-how in vessel occlusion (veins, arteries, and tubular structures) during surgical and interventional procedures in vascular trauma, vascular access, and other interventional procedures…Read More

Amsel Medical's Selected for Presentation at 37th EAST Annual Scientific Assembly

Amsel Medical announced that an abstract detailing its groundbreaking innovation, SCureTO™, Saving Limbs and Lives: A Novel Percutaneous Vessel Occlusion Device to Combat Junctional Hemorrhage in Trauma, has been accepted for scientific presentation at the 37th EAST Annual Scientific Assembly.  This presentation is scheduled on January 12, 2024, from 9:15 am to 9:30 am. This work underscores Amsel Medical's commitment to pushing the boundaries of medical innovation and improving patient outcomes in life-critical situations….Read More

SCureTO Trauma Solution Spotlighted at the Night Stalker Foundation Fund Raiser

Amsel Medical proudly supports the Night Stalker Foundation’s commemoration of the 30th Anniversary of Gothic Serpent, the Battle of Mogadishu, “Black Hawk Down.”  This event is an opportunity to honor the service and sacrifice of the 160th Special Operations Aviation Regiment (Airborne). The event will be held at the One World Trade Observatory on Thursday, October 19th, 2023 from 6:00PM – 9:00PM…..Read More

 

Amsel Medical Highlighted at VEITH Symposium

Amsel Medical Corp. highlighted a presentation on the SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) at the VEITH Symposium last week by Lowell S. Kabnick, MD. He described the need… Read More

Amsel Medical Announces $1.5 million AFWERX TACFI Grant Award

Tactical Funding Increase (TACFI) grants Amsel Medical significant further investment in support of improved urgent care for trauma. Amsel Medical Corporation recently… Read More

Amsel Medical Announces Appointment of Jeff Willis as Senior Director of Engineering

Amsel Medical Corp. today announced the appointment of Jeff Willis as Senior Director of Engineering to help drive the current product commercialization phase and implement the company’s strategy to address the demand for… Read More

Robert M. Rossell

Amsel Medical Announces Appointment of Robert M. Rossell as Chief Commercial Officer

Amsel Medical Corp. today announced the appointment of Robert M. Rossell as Chief Commercial Officer to drive the current commercial phase and implement the company’s strategy to address the demand for… Read more

Amsel Medical wins FDA nod for Endo Occluder

Amsel Medical said today that it won FDA 510(k) clearance for its Amsel Endo Occluder device intended for occluding blood vessels during endoscopic procedures… Read more

Amsel Medical Announces Appointment of Robert Manning as a New Board Member

Amsel Medical today announced that Robert Manning has been appointed to its Board of Directors.  Robert served as a Board Advisor prior to this appointment. 

James A. Heinz, Amsel Medical’s CEO, expressed his enthusiasm: “We are thrilled to welcome Robert to the Amsel Board. His extensive background in investment and corporate finance, combined with his commitment to early-stage ventures, will be instrumental as we advance our mission. Robert’s experience in bioscience and technology aligns perfectly with Amsel’s growth strategy, especially as we prepare for our upcoming initiatives.” ….Read More

Amsel Medical Announces Appointment of Chief Executive Officer

Amsel Medical Corporation is pleased to announce the appointment of James A. Heinz, MSL as Chief Executive Officer of Amsel effective July 30, 2024. Mr. Heinz began his service in October 2023 with Amsel as a Board Advisor, later joining Amsel as its Senior Vice President for Strategic Development.  ….. Read More

Dave Doster, CEO of Amsel Medical, presented at the esteemed LSI Emerging MedTech Summit on March 21, 2024, at Monarch Beach Resort

Regarded as “JPMorgan must-attend event for emerging MedTech companies”, the summit serves as a prime hub for leaders driving MedTech innovation. It's an unmatched forum for startups seeking funding and strategic partnerships to spark transformative healthcare solutions…. Read More

AMSEL Medical Announces Appointment of James A. Heinz, MSL as Senior Vice President Strategic Development

Amsel Medical Corporation announces the appointment of James A. Heinz as Senior Vice President Strategic Development to compliment our team as we commercialize the company and launch “game changing” technology that addresses the demand for minimally invasive, simple, and secure permanent vessel occlusion or temporary hemorrhage management…..Read More

Presenting Breakthrough Innovation at the Prestigious Joint Innovation Medical Symposium (JIMS)

Amsel Medical announced that they were selected to present at the Joint Innovation Medical Symposium (JIMS) at Pope Army Airfield/Fort Liberty, NC on November 9, 2023.

Amsel is one of only 20 companies invited to showcase their innovative technology and present their associated proposals for collaboration…..Read More

Amsel Medical Corp. selected for M2D2 IMPACT Cycle 4

Amsel Medical Corp. announced selection into the M2D2 IMPACT Cycle 4 accelerator program. IMPACT is a 12-week accelerator program that uses a unique one-on-one… Read More

Amsel Medical Announces Expanded Medical Advisor Group

Experienced team brings track record of quality product counsel for growth. Amsel Medical Corp. recently announced the expansion of its medical advisory team as the company advances the current product commercialization phase to address the demand for… Read More

The Next Evolution In Blood Vessel Occlusion

The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries… Read More

Amsel

Amsel Medical Announces Director of Clinical and Medical Affairs

Amsel Medical Corp. today announced the appointment of Lowell S. Kabnick as a consultant acting as Director of Clinical and Medical Affairs, as the company advances the current product commercialization phase to address the demand for… Read More

press-2.jpg

Amsel Medical Corporation Announces First In-Man Clinical Use of the Amsel Occluder Device at NYU Langone Medical Center.

Amsel Medical Corporation today announced First In-Man clinical use of the Amsel Occluder Device (AOD)1 at NYU Langone Medical Center, NY. The AOD2 was utilized during a variety of vascular surgical cases to ligate and occlude target vessels…Read More